Literature DB >> 1380229

(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro.

J A Coates1, N Cammack, H J Jenkinson, A J Jowett, M I Jowett, B A Pearson, C R Penn, P L Rouse, K C Viner, J M Cameron.   

Abstract

The (-)-enantiomer of 2'-deoxy-3'-thiacytidine (3TC) was found to be a potent and selective inhibitor of human immunodeficiency virus types 1 (HIV-1) and 2 (HIV-2) in vitro. We determined its antiviral activity against a number of laboratory strains of HIV-1 and HIV-2 in a range of CD4-bearing lymphocyte cell lines (mean 50% inhibitory concentration [IC50] range, 4 nM to 0.67 microM). 3TC was also active against a range of HIV-1 strains in peripheral blood lymphocytes (mean IC50 range, 2.5 to 90 nM). The IC50 for cytotoxicity in seven lymphocyte cell cultures, including human peripheral blood lymphocytes, ranged from 0.5 to 6 mM. 3TC had no detectable antiviral activity against a range of other viruses or in cells chronically infected with HIV-1 or HIV-2. The effects of time of addition of the compound and varying the multiplicity of infection on the antiviral activity of 3TC were determined. The results showed that 3TC is a potent and selective inhibitor of HIV-1 and HIV-2 replication in vitro.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1380229      PMCID: PMC189378          DOI: 10.1128/AAC.36.4.733

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro.

Authors:  J A Coates; N Cammack; H J Jenkinson; I M Mutton; B A Pearson; R Storer; J M Cameron; C R Penn
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

2.  AZT (zidovudine) may act postintegrationally to inhibit generation of HIV-1 progeny virus in chronically infected cells.

Authors:  R Rooke; M Tremblay; M A Wainberg
Journal:  Virology       Date:  1990-05       Impact factor: 3.616

3.  Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.

Authors:  H Mitsuya; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

4.  Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.

Authors:  M H St Clair; J L Martin; G Tudor-Williams; M C Bach; C L Vavro; D M King; P Kellam; S D Kemp; B A Larder
Journal:  Science       Date:  1991-09-27       Impact factor: 47.728

5.  Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells.

Authors:  R E Dornsife; M H St Clair; A T Huang; T J Panella; G W Koszalka; C L Burns; D R Averett
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

6.  Azidothymidine associated with bone marrow failure in the acquired immunodeficiency syndrome (AIDS).

Authors:  P S Gill; M Rarick; R K Brynes; D Causey; C Loureiro; A M Levine
Journal:  Ann Intern Med       Date:  1987-10       Impact factor: 25.391

7.  Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome (AIDS) and Kaposi sarcoma treated with zidovudine.

Authors:  R E Walker; R I Parker; J A Kovacs; H Masur; H C Lane; S Carleton; L E Kirk; H R Gralnick; A S Fauci
Journal:  Ann Intern Med       Date:  1988-03       Impact factor: 25.391

8.  The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  D D Richman; M A Fischl; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; M S Hirsch
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

9.  Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro.

Authors:  M Baba; R Pauwels; J Balzarini; P Herdewijn; E De Clercq; J Desmyter
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

10.  Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

Authors:  R Yarchoan; C F Perno; R V Thomas; R W Klecker; J P Allain; R J Wills; N McAtee; M A Fischl; R Dubinsky; M C McNeely
Journal:  Lancet       Date:  1988-01-16       Impact factor: 79.321

View more
  60 in total

1.  Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA.

Authors:  W E Delaney; T G Miller; H C Isom
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Antiretroviral agents inhibit infection of human cells by porcine endogenous retroviruses.

Authors:  S K Powell; M E Gates; G Langford; M L Gu; C Lockey; Z Long; E Otto
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

3.  Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.

Authors:  W E Delaney; R Edwards; D Colledge; T Shaw; J Torresi; T G Miller; H C Isom; C T Bock; M P Manns; C Trautwein; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

4.  Gag-Pol supplied in trans is efficiently packaged and supports viral function in human immunodeficiency virus type 1.

Authors:  M K Hill; C W Hooker; D Harrich; S M Crowe; J Mak
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.

Authors:  Elijah Paintsil; Ginger E Dutschman; Rong Hu; Susan P Grill; Wing Lam; Masanori Baba; Hiromichi Tanaka; Yung-Chi Cheng
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

Review 6.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

7.  Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.

Authors:  M Tisdale; S D Kemp; N R Parry; B A Larder
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

Review 8.  Clinical pharmacokinetics of lamivudine.

Authors:  M A Johnson; K H Moore; G J Yuen; A Bye; G E Pakes
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

9.  S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1.

Authors:  T Fujiwara; A Sato; M el-Farrash; S Miki; K Abe; Y Isaka; M Kodama; Y Wu; L B Chen; H Harada; H Sugimoto; M Hatanaka; Y Hinuma
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

10.  Impact of maternal and infant antiretroviral drug regimens on drug resistance in HIV-infected breastfeeding infants.

Authors:  Jessica M Fogel; Anthony Mwatha; Paul Richardson; Elizabeth R Brown; Tsungai Chipato; Michel Alexandre; Dhayendre Moodley; Ali Elbireer; Mark Mirochnick; Kathleen George; Lynne M Mofenson; Sheryl Zwerski; Hoosen M Coovadia; Susan H Eshleman
Journal:  Pediatr Infect Dis J       Date:  2013-04       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.